Brainstorm Cell Therapeutics Inc.

NasdaqCM:BCLI Stok Raporu

Piyasa değeri: US$7.1m

Brainstorm Cell Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Brainstorm Cell Therapeutics CEO'su Chaim Lebovits, Jan2023 tarihinde atandı, in görev süresi 1.83 yıldır. in toplam yıllık tazminatı $ 1.13M olup, şirket hissesi ve opsiyonları dahil olmak üzere 39.1% maaş ve 60.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.52% ine doğrudan sahiptir ve bu hisseler $ 108.58K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 6.7 yıldır.

Anahtar bilgiler

Chaim Lebovits

İcra Kurulu Başkanı

US$1.1m

Toplam tazminat

CEO maaş yüzdesi39.1%
CEO görev süresi1.8yrs
CEO sahipliği1.5%
Yönetim ortalama görev süresi1.8yrs
Yönetim Kurulu ortalama görev süresi6.7yrs

Son yönetim güncellemeleri

Recent updates

Brainstorm Cell Therapeutics: Upcoming BLA In ALS

Aug 21

BrainStorm Cell Therapeutics Q2 2022 Earnings Preview

Aug 12

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Aug 05
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Mar 22
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Nov 26
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS

May 30

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

May 02
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

BrainStorm Cell Therapeutics EPS beats by $0.07

Apr 26

Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?

Feb 21
Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?

BrainStorm Cell Therapeutics EPS misses by $0.18

Feb 04

Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation

Jan 17
Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation

BrainStorm completes dosing in Phase 2 MS Study

Dec 18

BrainStorm launches NurOwn Expanded Access Program

Dec 14

What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?

Dec 13
What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?

BrainStorm's NurOwn flunks in late-stage ALS study

Nov 17

CEO Tazminat Analizi

Chaim Lebovits'un ücretlendirmesi Brainstorm Cell Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$14m

Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$1mUS$442k

-US$17m

Sep 30 2023n/an/a

-US$17m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$24m

Dec 31 2022US$1mUS$500k

-US$24m

Sep 30 2022n/an/a

-US$25m

Jun 30 2022n/an/a

-US$24m

Mar 31 2022n/an/a

-US$23m

Dec 31 2021US$1mUS$500k

-US$24m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$29m

Mar 31 2021n/an/a

-US$30m

Dec 31 2020US$2mUS$500k

-US$32m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$29m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$1mUS$500k

-US$23m

Sep 30 2019n/an/a

-US$21m

Jun 30 2019n/an/a

-US$18m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018US$2mUS$500k

-US$14m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$5m

Dec 31 2017US$1mUS$391k

-US$5m

Tazminat ve Piyasa: Chaim 'nin toplam tazminatı ($USD 1.13M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 649.63K ).

Tazminat ve Kazançlar: Chaim şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Chaim Lebovits (53 yo)

1.8yrs

Görev süresi

US$1,128,795

Tazminat

Mr. Chaim Lebovits is President & Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from January 2023. Mr. Lebovits was Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from April 20...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Chaim Lebovits
President & CEO1.8yrsUS$1.13m1.52%
$ 108.6k
Irit Arbel
Co-Founder & Independent Vice Chair of the Board20.5yrsVeri yok0.20%
$ 13.9k
Alla Patlis
Interim CFO & Controller11.9yrsUS$146.78k0.082%
$ 5.8k
Uri Yablonka
Executive VP7.7yrsUS$247.06k0.16%
$ 11.4k
Hartoun Hartounian
Executive VP & COOless than a yearVeri yokVeri yok
Daniel Offen
Chief Scientific Advisorno dataVeri yokVeri yok
Mary Turner
Senior Vice President of Patient Advocacy & Government Affairs2.8yrsVeri yokVeri yok
Ibrahim Dagher
Executive VP & Chief Medical Officer1.3yrsVeri yok0.24%
$ 17.0k
Netta Blondheim-Shraga
Senior Vice President of Research and Developmentless than a yearVeri yokVeri yok

1.8yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: BCLI 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Irit Arbel
Co-Founder & Independent Vice Chair of the Board20.5yrsVeri yok0.20%
$ 13.9k
Uri Yablonka
Executive VP10.4yrsUS$247.06k0.16%
$ 11.4k
Jacob Frenkel
Independent Chairman of the Board4.7yrsVeri yok0.071%
$ 5.1k
Stanley Appel
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Andrew Card
Member of Business Advisory Board13.7yrsVeri yokVeri yok
Amit Bar-Or
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Rasheda Ali
Member of Business Advisory Board17.1yrsVeri yokVeri yok
Jerold Chun
Chairman of Scientific Advisory Board6.7yrsVeri yokVeri yok
Anthony Polverino
Independent Director6.8yrsUS$12.50k0.033%
$ 2.3k
Ralph Kern
Member of Scientific Advisory Board1.8yrsUS$4.46mVeri yok
Stacy Lindborg
Directorless than a yearUS$1.01m0.45%
$ 32.4k
Nir Naor
Independent Director1.4yrsVeri yokVeri yok

6.7yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BCLI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.7 yıldır).